Patient characteristics at study inclusion (N = 806)
| Patient-related characteristics . | Frequency . | Missing . |
|---|---|---|
| Female, n (%) | 399 (49.5) | 0 (0.0) |
| Age, median (IQR), y | 61 (53-69) | 0 (0.0) |
| BMI, median (IQR), kg/m2 | 24 (21-27) | 15 (1.9) |
| WHO performance status, n (%) | 16 (2.0) | |
| 0 | 523 (64.9) | NA |
| 1 | 208 (25.8) | NA |
| 2 | 55 (6.8) | NA |
| 3 | 4 (0.5) | NA |
| History of VTE, n (%) | 43 (5.3) | 0 (0.0) |
| Therapy-related characteristics, n (%) | ||
| Systematic therapy type | 0 (0.0) | |
| Chemotherapy | 389 (48.3) | NA |
| ICI and chemotherapy | 134 (16.6) | NA |
| ICI monotherapy | 124 (15.4) | NA |
| Targeted therapy and chemotherapy | 100 (12.4) | NA |
| Targeted monotherapy | 46 (5.7) | NA |
| ICI and targeted therapy | 13 (1.6) | NA |
| Antiplatelet therapy | 140 (17.4) | 0 (0.0) |
| Cancer-related characteristics, n (%) | ||
| Cancer type | 0 (0.0) | |
| Lung | 176 (21.8) | NA |
| Breast | 87 (10.8) | NA |
| Pancreas | 83 (10.3) | NA |
| Head and neck | 82 (10.2) | NA |
| Sarcoma | 70 (8.7) | NA |
| Colorectal | 64 (7.9) | NA |
| Stomach | 36 (4.5) | NA |
| High grade glioma | 32 (4.0) | NA |
| Other∗ | 176 (21.8) | NA |
| Cancer stage | 0 (0.0) | |
| Localized disease | 160 (19.8) | NA |
| Lymph node involvement | 144 (17.9) | NA |
| Metastatic disease | 502 (62.3) | NA |
| Newly diagnosed cancer | 434 (53.9) | 0 (0.0) |
| Recurrent cancer | 372 (46.1) | 0 (0.0) |
| Laboratory characteristics, median (IQR) | ||
| Hemoglobin, g/dL | 13 (11.4-14.1) | 8 (1.0) |
| Thrombocytes, G/L | 263 (212-334) | 8 (1.0) |
| Leukocytes, G/L | 7.4 (6.0-9.6) | 8 (1.0) |
| D-dimer, μg/mL | 0.7 (0.4-1.4) | 239 (29.7) |
| Patient-related characteristics . | Frequency . | Missing . |
|---|---|---|
| Female, n (%) | 399 (49.5) | 0 (0.0) |
| Age, median (IQR), y | 61 (53-69) | 0 (0.0) |
| BMI, median (IQR), kg/m2 | 24 (21-27) | 15 (1.9) |
| WHO performance status, n (%) | 16 (2.0) | |
| 0 | 523 (64.9) | NA |
| 1 | 208 (25.8) | NA |
| 2 | 55 (6.8) | NA |
| 3 | 4 (0.5) | NA |
| History of VTE, n (%) | 43 (5.3) | 0 (0.0) |
| Therapy-related characteristics, n (%) | ||
| Systematic therapy type | 0 (0.0) | |
| Chemotherapy | 389 (48.3) | NA |
| ICI and chemotherapy | 134 (16.6) | NA |
| ICI monotherapy | 124 (15.4) | NA |
| Targeted therapy and chemotherapy | 100 (12.4) | NA |
| Targeted monotherapy | 46 (5.7) | NA |
| ICI and targeted therapy | 13 (1.6) | NA |
| Antiplatelet therapy | 140 (17.4) | 0 (0.0) |
| Cancer-related characteristics, n (%) | ||
| Cancer type | 0 (0.0) | |
| Lung | 176 (21.8) | NA |
| Breast | 87 (10.8) | NA |
| Pancreas | 83 (10.3) | NA |
| Head and neck | 82 (10.2) | NA |
| Sarcoma | 70 (8.7) | NA |
| Colorectal | 64 (7.9) | NA |
| Stomach | 36 (4.5) | NA |
| High grade glioma | 32 (4.0) | NA |
| Other∗ | 176 (21.8) | NA |
| Cancer stage | 0 (0.0) | |
| Localized disease | 160 (19.8) | NA |
| Lymph node involvement | 144 (17.9) | NA |
| Metastatic disease | 502 (62.3) | NA |
| Newly diagnosed cancer | 434 (53.9) | 0 (0.0) |
| Recurrent cancer | 372 (46.1) | 0 (0.0) |
| Laboratory characteristics, median (IQR) | ||
| Hemoglobin, g/dL | 13 (11.4-14.1) | 8 (1.0) |
| Thrombocytes, G/L | 263 (212-334) | 8 (1.0) |
| Leukocytes, G/L | 7.4 (6.0-9.6) | 8 (1.0) |
| D-dimer, μg/mL | 0.7 (0.4-1.4) | 239 (29.7) |
BMI, body mass index; NA, not applicable; WHO, World Health Organization.
Includes biliary tract, esophagus, cancer of unknown primary, meningioma, renal cell carcinoma, low grade glioma, neuroendocrine cancer, lymphoma, mesothelioma, anal carcinoma, prostate, hepatocellular carcinoma, melanoma, testicular cancer, neuroendocrine tumor, bladder, thymus, hemangioblastoma, ovarian cancer, endometroid cancer, and thyroid.